PetMed Express Management

Management criteria checks 2/4

PetMed Express' CEO is Matt Hulett, appointed in Aug 2021, has a tenure of 2.67 years. total yearly compensation is $534.12K, comprised of 93.6% salary and 6.4% bonuses, including company stock and options. directly owns 3.01% of the company’s shares, worth €2.32M. The average tenure of the management team and the board of directors is 2.3 years and 2.7 years respectively.

Key information

Matt Hulett

Chief executive officer

US$534.1k

Total compensation

CEO salary percentage	93.6%
CEO tenure	2.7yrs
CEO ownership	3.0%
Management average tenure	2.3yrs
Board average tenure	2.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Matt Hulett's remuneration changed compared to PetMed Express's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$3m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$3m
Mar 31 2023	US$534k	US$500k	US$5m
Dec 31 2022	n/a	n/a	US$9m
Sep 30 2022	n/a	n/a	US$16m
Jun 30 2022	n/a	n/a	US$19m
Mar 31 2022	US$13m	US$279k	US$19m

Compensation vs Market: Matt's total compensation ($USD534.12K) is above average for companies of similar size in the German market ($USD406.99K).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.

CEO

Matt Hulett (52 yo)

2.7yrs

Tenure

US$534,119

Compensation

Mr. Mathew N. Hulett, also known as Matt, serves as Chief Executive Officer, President & Director at PetMed Express, Inc. since August 30, 2021. He served as Co-President of Rosetta Stone, Inc. since Janua...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mathew Hulett	CEO, President & Director	2.7yrs	US$534.12k	3.01% $ 2.3m
Christine Chambers	CFO, Principal Financial Officer	1.7yrs	US$651.48k	0.098% $ 75.3k
Mark Moseley	Chief Technology & Information Officer	2.3yrs	no data	0.21% $ 159.0k
Daniel Pingree	Chief Marketing Officer	2.3yrs	no data	0.11% $ 83.3k
Jacqueline Smith	Vice President of People	2.3yrs	no data	0.048% $ 37.1k
Wendy Zalai	Corporate Controller & Corporate Secretary	3.2yrs	no data	no data

2.3yrs

Average Tenure

Experienced Management: PQM's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mathew Hulett	CEO, President & Director	2.7yrs	US$534.12k	3.01% $ 2.3m
Gian Fulgoni	Independent Director	21.4yrs	US$218.20k	0.54% $ 414.6k
Sandra Campos	Independent Director	less than a year	no data	0.0080% $ 6.1k
Diana Purcel	Independent Director	2yrs	US$251.07k	0.046% $ 35.5k
Leslie C. Campbell	Independent Chairman of the Board	5.8yrs	US$203.20k	0.20% $ 151.4k

2.7yrs

Average Tenure

56yo

Average Age

Experienced Board: PQM's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

PetMed Express Management

Management criteria checks 2/4

Key information

Recent management updates

PetMed Express, Inc. Announces Management Changes

Independent Chairman of the Board recently bought €281k worth of stock

CEO, President & Director recently bought €94k worth of stock

High number of new directors

PetMed Express, Inc., Annual General Meeting, Aug 03, 2023

PetMed Express, Inc. Appoints Sandra Y. Campos to its Board of Directors

Recent updates

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. to Report Q3, 2024 Results on Feb 08, 2024

PetMed Express, Inc. Announces Management Changes

Independent Chairman of the Board recently bought €281k worth of stock

CEO, President & Director recently bought €94k worth of stock

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.13 profit in 2Q 2023)

PetMed Express, Inc. Makes Decision to Suspend the Quarterly Dividend Effective the Quarter Ended September 30, 2023

PetMed Express, Inc. to Report Q2, 2024 Results on Oct 30, 2023

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: US$0.044 loss per share (vs US$0.14 profit in 1Q 2023)

PetMed Express, Inc. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

High number of new directors

Full year 2023 earnings released: EPS: US$0.011 (vs US$1.05 in FY 2022)

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on June 12, 2023

PetMed Express, Inc., Annual General Meeting, Aug 03, 2023

PetMed Express, Inc. Appoints Sandra Y. Campos to its Board of Directors

PetMed Express, Inc. to Report Q4, 2023 Results on May 22, 2023

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.21 profit in 3Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on February 27, 2023

Investor sentiment improves as stock rises 17%

PetMed Express, Inc. to Report Q3, 2023 Results on Feb 06, 2023

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.

Second quarter 2023 earnings released: EPS: US$0.13 (vs US$0.32 in 2Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on November 30, 2022

PetMed Express, Inc. to Report Q2, 2023 Results on Nov 07, 2022

Now 20% undervalued

Upcoming dividend of US$0.30 per share

First quarter 2023 earnings released: EPS: US$0.14 (vs US$0.22 in 1Q 2022)

Petmed Express, Inc. Declares Quarterly Dividend, Payable on August 19, 2022

PetMed Express, Inc. Announces Executive Changes

PetMed Express, Inc. to Report Q1, 2023 Results on Jul 25, 2022

PetMed Express, Inc., Annual General Meeting, Jul 28, 2022

PetMed Express, Inc., Annual General Meeting, Jul 28, 2022

Full year 2022 earnings released: EPS: US$1.05 (vs US$1.53 in FY 2021)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on May 27, 2022

PetMed Express, Inc. to Report Q4, 2022 Results on May 09, 2022

PetMed Express, Inc. Appoints Diana Garvis Purcel to Board of Directors, Effective April 4, 2022

Upcoming dividend of US$0.30 per share

PetMed Express, Inc. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2022 earnings released: EPS US$0.32 (vs US$0.42 in 2Q 2021)

Independent Director Frank Formica has left the company

First quarter 2022 earnings released: EPS US$0.22 (vs US$0.39 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$1.53 (vs US$1.29 in FY 2020)

Full year 2021 earnings released: EPS US$1.53 (vs US$1.29 in FY 2020)

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on May 21, 2021

Independent Chairman Robert Schweitzer has left the company

PetMed Express, Inc. Announces Executive Changes

Corporate Secretary & General Counsel has left the company

Investor sentiment deteriorated over the past week

CFO & Treasurer recently sold €206k worth of stock

Third quarter 2021 earnings released: EPS US$0.38 (vs US$0.34 in 3Q 2020)

Revenue beats expectations

Revenue beats expectations

Revenue beats expectations

Revenue beats expectations

Third quarter 2021 earnings released: EPS US$0.38

New 90-day high: €28.65

PetMed Express, Inc. to Report Q3, 2021 Results on Jan 19, 2021

New 90-day high: €27.42

Second quarter 2021 earnings released: EPS US$0.42

Revenue misses expectations

New 90-day low: €24.00